Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial of bendamustine and rituximab plus placebo vs bendamustine and rituximab plus idelalisib (NCT01569295). The primary endpoint was progression-free survival (PFS), which was favorable to adding idealisib. There was also an overall survival (OS) advantage to adding idealisib. Dr Zelenetz further discusses the side effects of this drug combination.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.